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Abstract
In total, 40 Pseudomonas aeruginosa isolates from cystic ﬁbrosis (CF) patients were included in this study. Twenty of these were col-
lected in 1994 and 1997, from six CF patients, and the rest were collected from different CF patients in 2000 and 2001. The rela-
tive expression of mRNA for the efﬂux pump protein MexY was determined by real-time PCR and correlated with susceptibilities
to amikacin and tobramycin. The chromosomal genes mexZ, rplY, galU, PA5471 and nuoG, which were found to have a role in the
gradual increase in MICs of aminoglycoside antibiotics in laboratory mutants of P. aeruginosa, were analysed. MexY mRNA overpro-
duction was found in 17 ⁄ 20 isolates collected in 1994 and 1997, and was correlated with decreased susceptibility to aminoglyco-
sides. Alteration of the MexXY–OprM efﬂux system has been the main mechanism of resistance to aminoglycoside antibiotics in CF
P. aeruginosa isolates over the 3-year period. In several isolates, expression of the PA5471 gene product might have some effect on
elevated MICs of aminoglycosides. Inactivation of rplY, galU and ⁄ or nuoG may explain the gradual increase in MICs of aminoglyco-
sides in laboratory mutants but probably not in the CF environment, as rplY and galU were unaltered in all isolates, and nuoG was
not expressed in only one isolate. No 16S rRNA A-site mutations were found in any of the four copies of the gene in 13 investi-
gated isolates.
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Introduction
Pseudomonas aeruginosa is the key pathogen in chronic bac-
terial airway infection in patients with cystic ﬁbrosis (CF).
Most often, the treatment of CF patients involves repeated
long-term oral, aerosolized and ⁄or intravenous administra-
tion of various groups of antibiotics. Once a P. aeruginosa
infection is established, it is seldom eradicated, although the
bacterial load can be decreased with aminoglycosides, b-lac-
tam antibiotics and ﬂuoroquinolones. Aminoglycoside resis-
tance in clinical isolates from CF patients occurs mainly
because of reduced drug uptake or accumulation as a result
of impermeability-type resistance and ⁄or of other mechan-
isms adaptive resistance to the antibiotic.
P. aeruginosa strains colonizing CF lungs undergo antibiotic
treatment over several years, which results in clonal expan-
sion and selection for higher MICs. In the case of aminogly-
coside antibiotics, this increase in MICs is usually due to
chromosomal changes rather than acquisition of genetic ele-
ments, e.g. plasmids, via horizontal transfer [1,2]. Previous
studies have shown that the MexXY–OprM efﬂux system is
the most important aminoglycoside resistance-conferring sys-
tem in CF P. aeruginosa (CFPA) isolates [3–5]. It can lead to
both impermeability-type and adaptive-type aminoglycoside
resistance in CFPA isolates, and its expression is inducible by
its substrate antibiotics [6]. In a recent study [7], it has been
shown that in laboratory mutants of P. aeruginosa, ﬁve chro-
mosome-encoded genes (rplY, galU, nuoG, mexZ and PA5471)
are involved in the gradual increase in the MICs
of aminoglycosides. MexAB–OprM was also reported to con-
tribute to aminoglycoside resistance in a low ionic strength
environment [8]. The prevalence of efﬂux pump overproduc-
tion in clinical strains of P. aeruginosa may range from 14%
to 75% [9]. However, in non-CF isolates of P. aeruginosa,
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efﬂux-mediated aminoglycoside resistance only contributes a
moderate two-fold increase. In the CF lung, P. aeruginosa
undergoes a variety of metabolic changes through genetic
modiﬁcation; additional mechanisms have been proposed for
some CF strains for this gradual increase in MICs of amino-
glycosides [4]. To focus more on the genetic changes in
P. aeruginosa, the mRNA production of the efﬂux pump pro-
tein MexY was tested and ﬁve chromosomal genes from 20
CFPA isolates collected at two different time points with a
3-year interval were sequenced. Another 20 CFPA isolates
from different patients from a previous study were included
[10]. These data suggest that in pulmonary infection in
CF patients, MexXY remains the main known system mediat-
ing aminoglycoside resistance in P. aeruginosa as a result
of numerous changes in the regulatory gene mexZ.
Materials and Methods
Bacterial isolates
Forty CFPA isolates were studied. Fifteen aminoglycoside-
resistant and ﬁve aminoglycoside-sensitive P. aeruginosa iso-
lates were collected from chronically colonized CF patients
at the Cystic Fibrosis Centre at Karolinska University Hospi-
tal, Huddinge, Sweden (Table 1), and have previously been
studied for production of MexY mRNA and MICs of differ-
ent antibiotics [10].
Here, changes in other chromosomal determinants that
have been reported to have a role in aminoglycoside resis-
tance were sought. The genes coding for ribosomal
protein L25 (rplY) and UDP-glucose pyrophosphorylase (galU)
were sequenced, and the integrity (presence or absence of
stop codons) of the nuo operon (encoding the subunits of the
type I (energy-conserving) NADH dehydrogenase, a key com-
ponent of the respiratory chain) was analysed by qualitatively
assessing the mRNA expression of two genes, i.e. nuoH and
nuoN, using real-time PCR. The level of PA5471 mRNA
expression was also measured quantitatively in these isolates.
Another 20 P. aeruginosa isolates collected from six CF
patients, aged 27–33 years, in 1994 (nine isolates) and 1997
(11 isolates) at the CF Centre, Copenhagen, Denmark, were
included in order to follow the development of resistance
over time (Table 2). These patients were treated according
to the standard therapy for CF [11]. All the patients had
been exposed to repeated treatments with aminoglycosides
along with ciproﬂoxacin since 1986, and had received at least
TABLE 1. Primers used in this study
Primer Sequence Reference
Annealing
temperature (C)
PCR and Sequencing
mexZ-1 (20mer) 5¢-AAGGGCGTGGGCACCACTGC-3¢ [10] 61.0
mexZ-2 (20mer) 5¢-GGACCAGCGCAGGCACCTGA-3¢ [10]
mexZ2p-U (22mer) 5¢-GGCGTTTCTGTAACATATCCTT-3¢ This study 59.1
mexZ2p-L (18mer) 5¢-GCGAGGAAGACGCCCAGC-3¢ This study
mexZS1 (18mer) 5¢-GCGGGTGCTGGAGATCCT-3¢ This study
mexZS2 (18mer) 5¢-AGGATCTCCAGCACCCGC-3¢ This study
mexOZ-1 (20mer)* 5¢-CAGCGAGCCGGTCCATTGGA-3¢ [10] 60.0
mexOZ-2 (20mer)* 5¢-TCGCACATCGCCAGGCAGAC-3¢ [10]
galUF140-U (21mer) 5¢-CGAGCGCAGCCTGATTAGACT-3¢ This study 61.0
galUR645-L (21mer) 5¢-GGAGCAGCG GAACTGGTTGTA-3¢ This study
galUF565-U (16mer) 5¢-AGCCGTTCGCCGTGGT-3¢ This study 61.0
galUR1121-L (21mer) 5¢-ACAGCTCAGGTAGGGCGGATA-3¢ This study
rplYF144-U (17mer) 5¢-ATCGCCCGAACGCTGGT-3¢ This study 61.0
rplYL902-L (21mer) 5¢-ATGCCGGGTCTGGTCGTATTC-3¢ This study
APHIIB-1 5¢-ATGCATGATGCAGCCACCTCCAT-3¢ [25] 56.0
APHIIB-4 5¢-CCTACTCTAGAAGAACTCGTCCA-3¢ [25]
AAC6IbU 5¢-GAGTGGGGCGGAGAAGA-3¢ [10] 58.0
AAC6IbL 5¢-CCCAAGCCTTTGCCCAGT TG-3¢ [10]
ANT4IIBU 5¢-TTACCGCACCTGGATAGAGC-3¢ [10] 58.0
ANT4IIBL 5¢-GATGGGGATCAACAATGTCG-3¢ [10]
Pyrosequencing
TRDR-U (21mer) 5¢-TCAGAATGTCACGGTGAATAC-3¢ This study 56.0
TRDR-L (19mer) 5¢-BIOTIN-TTCGTGTGGGAGCTTATGA-3¢ This study
TRDRSeq-1 (18mer) 5¢-CTTGTACACACCGCCCGT-3¢ This study
TRDRSeq-2 (18mer) 5¢-GTTACCACGGAGTGATTC-3¢ This study
Real-time PCR
mexY-1 (21mer) 5¢-GGACCACGCCGAAACCGAACG-3¢ [10] 62.0
mexY-2 (21mer) 5¢-CGCCGCAACTGACCCGCTACA-3¢ [10]
rpsL-1 (21mer) 5¢-GCTGCAAAACTGCCCGCAACG-3¢ [10] 62.0
rpsL-2 (21mer) 5¢-ACCCGAGGTGTCCAGCGAACC-3¢ [10]
nuoHF657-U (18mer) 5¢-GCAGGAACTGGCGGACGG-3¢ This study 62.0
nuoHL823-L (21mer) 5¢-GGTCTTGGCGGCGAAGTAGAA-3¢ This study
nuoNF148-U (21mer) 5¢-CTGTCGCTGCTGCCGGTCCTC-3¢ This study 62.0
nuoNL297-L (21mer) 5¢-TACAGCTCTTCGCGGTTACCC-3¢ This study
PA5471-U (17mer) 5¢-CGACATCGGCTGTGGCA-3¢ This study 62.0
PA5471-L (19mer) 5¢-AGTCGCTCCAGGTCTCGTC-3¢ This study
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15 antibiotic courses (14 days ⁄ course) by 1994. These
P. aeruginosa isolates had previously been typed by pulsed-
ﬁeld gel electrophoresis (patients CF21, CF59, CF86 and
CF89) or by ribotyping (patients CF166 and CF222) [12]. All
these earlier isolates were subjected to a similar type of ana-
lysis as described previously [10].
Strain PAO1 (B. W. Holloway, Monash University, Mel-
bourne, Australia) was used as a control strain.
Antibiotic susceptibility testing
The MICs were determined using the Etest (Biodisk, Solna,
Sweden) on Mueller–Hinton (Oxoid, Hampshire, UK). The
MIC determination of Swedish CF isolates was described in
a previous paper [10].
PCR and DNA sequencing
Chromosomal and plasmid DNA from all Pseudomonas iso-
lates was extracted using the QIAamp DNA Mini Kit and
QIAquick spin minipreps (Qiagen, Hilden, Germany), accord-
ing to the manufacturer’s instruction with slight modiﬁca-
tions, and used for PCR. PCR ampliﬁcation was performed
according to the standard protocol for AmpliTaq DNA poly-
merase (Applied Biosystems, Foster City, CA, USA) of all
genes, except that 2% dimethylsulphoxide (Sigma-Aldrich,
St Louis, MO, USA) was added to the master mix to amplify
the mexZ gene. The primers used to amplify different Pseudo-
monas genes are listed in Table 3.
The PCR products were puriﬁed using the QIAquick-spin
PCR puriﬁcation kit (Qiagen). Nucleotide sequences of the
PCR products were determined on both strands using the
Big-Dye terminator technology with capillary electrophor-
esis in an ABI 310 analyzer (Applied Biosystems). Nucleo-
tide and deduced amino acid sequences were analysed
using PC FinchTV software (http://www.geospiza.com/
ﬁnchtv/), the ClustalW multiple sequence alignment soft-
ware at the European Bioinformatics Institute (http://
www.ebi.ac.uk/Tools/clustalw/index.html), and the Expasy
Molecular Biology Server at the Swiss Institute of Bioinfor-
matics, Geneva, Switzerland (http://www.expasy.ch/tools/
dna.html). Each strand was sequenced twice, and no ambi-
guities in PCR ampliﬁcation or sequencing were detected.
The nucleotide sequence information was obtained from
the Pseudomonas Genome Project (http://v2.pseudomonas.-
com).
RNA puriﬁcation and cDNA synthesis
RNA extraction and cDNA synthesis were performed as
described previously [10]. The total RNA concentration was
measured using a NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). Two
microlitres of a solution of total RNA (0.5 lg ⁄lL) was used
to synthesize cDNA using the Transcriptor First Strand
cDNA Synthesis Kit for RT PCR (Roche Diagnostics GmbH,
Mannheim, Germany).
TABLE 2. MICs, amino acid alterations and relative production of mRNA in Pseudomonas aeruginosa isolates from six cystic
ﬁbrosis patients (1994 and 1997) from the Danish Cystic Fibrosis Centre
Patient Isolate (year)
MIC (mg ⁄ L) Alteration in: Relative mRNA production
AMK TOB CIP exZ ⁄MexZ mexY PA5471
PAO1 2 0.5 0.12 – 1 1
CF166 A1 (1994) >256 8 1 Frameshifta 15 1
A2 (1997) 32 2 4 Frameshifta 12 1
A3 (1997) 128 4 1 Frameshifta 51 2
CF222 B1 (1994) 2 4 2 L205P 61 2
B2 (1994) >256 12 2 L205P 137 4
B3 (1997) >256 1 8 L205P 79 1
B4 (1997) 64 4 0.5 Frameshifta 111 2
CF86 C1 (1994) 16 2 2 Frameshifta 3 1
C2 (1994) 128 128 2 Frameshifta 334 1
C3 (1997) 128 6 8 Frameshifta 48 <1 (0.60)
C4 (1997) 64 4 2 Frameshifta 75 1
CF59 D1 (1994) 24 2 2 L205P 3 5
D2 (1997) >256 >256 4 L205P 255 1
D3 (1997) >256 8 0.5 Frameshifta 278 1
CF21 E1 (1994) 16 2 0.5 Deletionb 104 2
E2 (1994) 32 1 1 Deletionb 162 2
E3 (1997) 32 2 4 Frameshifta 235 <1 (0.80)
E4 (1997) 32 2 1 Deletionb 78 2
CF89 F (1994) 16 2 0.5 Frameshifta 41 <1 (0.70)
G (1997) 8 1 2 A47V 1 3
CIP, ciproﬂoxacin; AMK, amikacin; TOB, tobramycin; L, leucine; P, proline; A, alanine; V, valine.
The MIC breakpoints according to the NCCLS for different antibiotics are as follows: CIP, R ‡4 mg ⁄ L, S £1 mg ⁄ L; AMK, R ‡32 mg ⁄ L, S £16 mg ⁄ L; and TOB, R ‡8 mg ⁄ L,
S £ 4 mg ⁄ L.
aInsertion of 16 nucleotides (GCGGGCGCGGCGAACT) downstream from position 450 results in a frameshift beyond the Arg codon 153.
bFifty-seven amino acids have been deleted from positions 135–192.
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Quantitative and qualitative real-time PCR
Expression of the mexY and PA5471 genes was measured by
quantitative real-time PCR according to the procedure
described elsewhere [13]. A real-time PCR assay was also
used to assess the normal expression of the nuo operon in a
qualitative manner by analysing the amplicon dissociation
with the LightCycler DNA analysis software. All the primer
sequences used in the real-time PCR assay are shown in
Table 1. The rpsL gene was used as internal control. The
real-time PCR assay was done in duplicate for all genes ana-
lysed, and the relative expression of mRNA was calculated.
The mRNA levels of a speciﬁc gene were calculated by com-
parison with rpsL [13]. A strain was considered to hyperpro-
duce mRNA for pump proteins if the corresponding cDNA
level was ‡5 times that observed in PAO1.
Pyrosequencing of the 16S rRNA A-site
Pyrosequencing was carried out according to the standard
protocol recommended by the manufacturer (Biotage AB,
Uppsala, Sweden), with slight modiﬁcations. In brief, 2 ng ⁄lL
of chromosomal DNA was used as a template to amplify a
220-bp 16S rRNA gene fragment from the 3¢-end using PCR
primers TRDR-U and TRDR-L-biotin (Table 1). Five ll of
template was used in a 50 ll reaction.
The ampliﬁed fragment included the A -site sequence of
16S rRNA. Primer TRDR-1 was used as a sequencing primer
for nucleotide positions 1399–1415 and primer TRDR-2
for positions 1484–1492 The pyrosequencing reaction was
performed using the 96 SQA reagent kit (Biotage, Uppsala,
Sweden) with the enzyme and substrate mixtures and the
four nucleotides as provided by the manufacturer. The result
of pyrosequencing was accepted on the basis of the quality
ratings obtained with the software provided with the kit and
then analysed visually.
The presence of double or multiple peaks for a single
nucleotide position was considered to indicate a point muta-
tion in any one of the four copies of the 16S rRNA gene.
Results and Discussion
Resistance rates in CFPA isolates are generally much higher
than in those from non-CF patients, due to extensive anti-
biotic use, and the adaptive nature and the mode of growth
of P. aeruginosa in the CF lung [14].
Among the Danish CFPA isolates, according to ﬁngerprint-
ing, all but that of patient CF89 were of the same type in
1994 and 1997 [12]. Four of the six patients (Table 2) car-
ried isolates that were classiﬁed as multiresistant
(isolates A1, B2, C2, D2 and D3) according to the criteria of
the American CF Foundation, i.e. resistant to all agents in at
least two of the following groups of antibiotics: b-lactams,
TABLE 3. MICs, amino acid alterations and relative production of mRNA in cystic ﬁbrosis Pseudomonas aeruginosa isolates
from patients from the Swedish Cystic Fibrosis Centre
Isolate
MIC (mg ⁄ L) Alteration in:
Relative mRNA
production
AMK TOB CIP mexZ ⁄MexZ Intergenic mexZ–mexX region mexY PA5471
Sensitive
PAO1 2 1 0.125 – – 1 1
Cfz21 4 1 0.125 – – 0.1 1
Cfz17 2 1 0.25 – – 0.4 2
Cfz18 1 1 0.5 – – 0.7 2
Cfz22 2 1 4 Leu(CTG)4 ﬁ Pro(CCG) A42G, C207T 1.6 1
Cfz13 4 1 1 Insertiona – 58 1
Resistant
Cfz08 128 8 2 Leu(CTC)105 ﬁ Arg(CGA) DG(39) 0.1 0.01
Cfz04 32 2 0.125 Cys(TGC)80 ﬁ Arg(CGC) Insertionb 2.5 0.14
Cfz26 16 2 2 – – 3.4 1
Cfz03 32 4 8 DGT(205) – 36 1
Cfz06 64 4 4 Glu(GAA)116 ﬁ Lys(AAA) – 55 0.34
Cfz15 64 4 4 Insertiona – 57 1
Cfz10 256 4 4 Arg(CGC)32 ﬁ Cys(TGC) – 75 1
Cfz09 16 2 2 DTTCA(233) C215T 77 4
Cfz14 128 4 0.5 Insertiona – 87 2
Cfz07 128 8 >32 – A178G 153 1
Cfz01 64 4 8 – – 185 4
Cfz16 64 2 8 Leu(CTG)4 ﬁ Pro(CCG) – 209 9
Cfz12 128 8 8 – C224T 258 6
Cfz05 128 8 0.5 Arg(CGC)159 ﬁ Pro(CCG) – 325 2
Cfz02 64 4 1 Gln(CAG)107 ﬁ Pro(CCG) Insertionc 727 6
CIP, ciproﬂoxacin; AMK, amikacin; TOB, tobramycin.
aInsertion of six nucleotides ACAAGA at nucleotide positions 68–73, original frame restored.
bInsertion of G between nucleotides 195 and 196.
cInsertion of C between nucleotides 149 and 150.
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aminoglycosides and ﬂuoroquinolones [15].The mean MICs
of ciproﬂoxacin and amikacin were twice as high for the iso-
lates from 1997 as for those from 1994, but no increase was
found for tobramycin.
The 20 Swedish CFPA isolates (Table 1) were from differ-
ent patients, and there was no cross-transmission among
patients as judged from pulsed-ﬁeld gel electrophoresis pat-
terns (data from the Scandinavian Cystic Fibrosis Study Con-
sortium).
The MexY mRNA was commonly overproduced among
the Danish CFPA isolates; in 17 of the 20 strains, the mRNA
levels were more than ﬁve times that of PAO 1 (Table 2).
This overexpression seems to have an effect on suscept-
ibility to amikacin, as in every case except one, increased
overproduction of MexY mRNA was associated with
decreased susceptibility to amikacin (MIC ‡16 mg ⁄ L).
Twelve of the 15 Swedish aminoglycoside-resistant CFPA
isolates showed a marked increase in the level of expression
of MexY mRNA. Isolates Cfz26, Cfz08 and Cfz04 showed
lower expression of MexY mRNA, even though these three
isolates had changes in mexZ and ⁄or the intergenic region
between mexZ and mexX. Isolates Cfz26 and Cfz08 were
slow-growing; in addition, isolate Cfz08 was a small-colony
variant. Isolate Cfz26 also produced relatively higher
amounts of MexZ mRNA, which may explain its lower level
of MexY mRNA production [10].
The TetR family transcriptional regulator MexZ [5,16],
which has a common N-terminal helix–turn–helix DNA-bind-
ing motif [17], binds to mexZ–mexX intergenic DNA at bp
)104 to )66 upstream of mexX, and negatively regulates
expression of the MexXY operon [3]. In MexZ of
isolates E1, E2 and E4 from patient CF21, 57 amino acids
were deleted from positions 135–192, and interestingly, the
original reading frame was maintained. In these three isolates,
the overproduction of MexY mRNA demonstrates the inabil-
ity of MexZ to stop transcription, resulting in 80–150-fold
increased expression of mexY as compared to the wild-type
strain PAO1 (Table 2) [12]. Eleven of 20 CF isolates had an
insertion of 16 nucleotides (GCGGGCGCGGCGAACT)
downstream from position 450, which resulted in a frame-
shift beyond the arginine codon 153, and the reading frame
was not restored. Among the isolates from three patients
(CF222, CF59 and CF21), this frameshift mutation was found
only in isolates isolated in 1997, but all P. aeruginosa isolates
isolated from patients CF86 and CF166 in 1994 as well as in
1997 carried this mutation. The effect of this mutation on
MexY mRNA overproduction was prominent in all isolates
except C1, which produced only three times the amount of
MexY mRNA produced by the control strain PAO1. In all
these isolates, the MICs of amikacin were signiﬁcantly higher,
ranging from 16 to >256 mg ⁄ L. Among the CFPA isolates
without any frameshift or deletion mutation, isolates B1, B2,
B3, D1 and D2 had a single nucleotide change, T614 ﬁ C,
which resulted in the Leu205 ﬁ Pro substitution at the C-
terminal end of MexZ. The signiﬁcance of this point mutation
is unknown, but a similar mutation has been reported by
Vogne et al. in a CF strain (2117R) [4]. Isolate D2 (from
1997) showed highly elevated production of MexY mRNA,
and the MIC of amikacin was >256 mg ⁄ L. However,
isolates D1 (from 1994) failed to produce signiﬁcantly ele-
vated levels of MexY mRNA, and the MIC of amikacin was
only 24 mg ⁄ L, probably ruling out an effect of this mutation
on the regulation of the MexXY efﬂux system.
By contrast, strain G (from 1997) had a nucleotide change,
C140T, resulting in the point mutation A47V in the N-term-
inal end of MexZ, but this strain produced MexY mRNA at a
wild-type level with a much less elevated MIC of amikacin as
compared to other isolates. This isolate and its counterpart
F from 1994 were dissimilar. Different mutations in mexZ in
isolates from CF patients are common [18], resulting in sig-
niﬁcant overexpression of mexY, although there is no simple
correlation with MIC levels. Interestingly, a difference
between the Swedish and the Danish CFPA isolates is that
all Danish isolates had a wild-type mexZ–mexX intergenic
region, in contrast to seven of the 20 Swedish isolates.
The pattern of changes in mexZ that was observed in
Swedish CFPA isolates was different from that in Danish CF
isolates, ranging from point mutations to amino acid substitu-
tions, insertions and deletions (Table 3) [10]. Isolates Cfz04,
Cfz07 and Cfz12 had wild-type mexZ but they harboured
insertions and point mutations in the intergenic region
between mexZ and mexX, in contrast to isolate Cfz01, which
had a wild-type sequence of both mexZ and the mexZ–mexX
intergenic region but still overproduced MexY mRNA.
It has been recently reported that the gene PA5471 is
inducible by the same ribosome-targeting drugs that induce
the MexZ-regulated MexXY operon, and that it plays a role
in MexXY-mediated antimicrobial resistance [19]. Mutant
strains with a non-functional PA5471 gene have been shown
to be compromised for induction of MexXY expression by
ribosome-targeting drugs and for MexXY–OprM-mediated
antimicrobial resistance [19]. Expression of PA5471 was sig-
niﬁcantly upregulated, by a factor of 3–5, in two Danish iso-
lates (D1 and G), but these isolates did not overproduce
MexY mRNA (Table 2).
Among the Swedish isolates, ﬁve of the 12 isolates with
overexpression of mexY (>30-fold that observed in PAO1)
also overexpressed PA5471 (‡4-fold that observed in
PAO1), suggesting that the expression of these genes is
linked. However, most of these isolates had mutations in
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mexY and the intergenic mexZ–mexY region, which also inﬂu-
enced the expression of mexY. Morita et al. [19] have sug-
gested that the combination of changes in mexZ and elevated
levels of the PA5471 gene product can give rise to higher
production of MexY and thereby contribute to an increase
in the MICs of aminoglycosides for CFPA isolates, However,
two isolates without overproduction of the PA5471 gene
showed MexY mRNA production >100-fold that of PAO1,
which indicates the existence of additional regulatory
mechanisms.
The Swedish [10] as well as the Danish CFPA isolates
were negative for the plasmid-borne genes aac(6¢)-Ib and
ant(4¢)-IIb and the chromosomal gene aph(3¢)-IIps, which spe-
cify aminoglycoside-modifying enzymes and confer resistance
mainly to amikacin. The drug-modifying enzymes are encoded
by genes that are often transmissible among organisms [20]
and in very few cases are enzymatic mechanisms of aminogly-
coside resistance combined with impermeability-type resis-
tance (efﬂux-mediated resistance mechanism) [5].
Another report [21] suggests that non-CFPA isolates are
in most cases resistant because of the presence of aminogly-
coside-modifying enzymes.
Gradual increases in MICs of aminoglycosides due to
mechanisms other than altered efﬂux pump activities or ami-
noglycoside-modifying enzymes have been reported. Mutants
of strain PAO1 with Tn5-Hg insertions in any of the chro-
mosomal genes nuoG, galU, mexZ or rplY caused a two-fold
increase in the MICs of aminoglycosides [7]. In the CF lung,
accumulation of these types of chromosomal changes might
contribute to gradual increases in the MICs of aminoglyco-
sides for P. aeruginosa isolates. In this study, the entire galU
and rplY genes from all isolates have been sequenced in the
search for unexpected stop codons or any other changes
that lead to the production of altered proteins. The NADH
dehydrogenase I chain G gene, nuoG, belongs to the operon
nuoABDEFGHIJKLMN.
To conﬁrm that the operon is transcribed completely, the
mRNA production of two genes, nuoH and nuoN, were quali-
tatively analysed by melting curve analysis using real-time PCR.
Both the Danish and the Swedish CFPA isolates were
found to have wild-type amino acid sequences in the rplY and
galU products. On the other hand, only one (Cfz02) out of
40 P. aeruginosa isolates tested had a disrupted nuoABDEF-
GHIJKLMN operon according to real-time PCR analysis. This
isolate (MIC of amikacin: 64 mg ⁄ L) produced 727 times the
amount of MexY mRNA as the reference strain, and had
changes both in mexZ and in the mexZ–mexX intergenic
region . However, as the protonmotive force may be
impaired in this strain, it is probable that the efﬂux pumps
are not fully functional.
Thus, the disrupted nou operon might contribute to ami-
noglycoside resistance in this isolate.
Aminoglycoside antibiotics target the A-site located at the
3¢-end of the 16S rRNA and eventually lead to misreading of
the genetic code. Point mutations in this region contribute
to resistance to aminoglycoside antibiotics in Escherichia coli,
and possibly also in P. aeruginosa. The ribosomal A-site of
P. aeruginosa consists of nucleotides 1400–1408 and 1489–
1500 (E. coli numbering system). Among these nucleotides, a
single A1408G change confers resistance to amikacin and
other 2-deoxystreptamine compounds in E. coli [22]. More-
over, a mutation in any of the uracil residues forming the
U1406–U1495 pair, or a double mutation in both, confers
high-level aminoglycoside resistance in some other organ-
isms, including mycobacteria [23,24]. As P. aeruginosa has
four 16S rRNA gene copies and the presence of any A-site
mutation in a single copy or in multiple copies could result
in higher MICs as the number of mutated copies increase.
All 16S rRNA gene copies are ﬂanked by tRNA-Ile (http://
V2.pseudomonas.com) genes, which makes it difﬁcult to dif-
ferentiate among the individual copies. Among a total of 40
CFPA isolates, ﬁve Danish (A1, B2, C1, D2 and D3) and
eight Swedish (Cfz01, 05, 07, 08, 10, 12, 17 and 22) isolates
were analysed for the presence of A-site mutations by pyro-
sequencing. All isolates had wild-type 16S rRNA gene
sequences. Thus, mutations in the genes for 16S rRNA may
be uncommon in aminoglycoside-resistant P. aeruginosa iso-
lates.
In conclusion, the main mechanism responsible for resis-
tance to aminoglycosides in P. aeruginosa strains from CF
patients is the alteration of MexXY–OprM efﬂux pump pro-
duction, regulated by the genes mexZ and PA5471. Thirty-
four of 35 amikacin-resistant and three of six sensitive CFPA
strains had mutations in mexZ and ⁄or the intergenic mexZ–
mexX region. Signiﬁcant upregulation of PA5471 was found
in seven isolates, all of which, except one, were highly resis-
tant to amikacin and overexpressed mexZ. There is no sim-
ple correlation between mutations in mexZ or the mexZ–
mexX intergenic region and expression of mexZ, and MICs of
amikacin. This indicates that other, unknown, genes are
involved in the regulation of mexZ. No mutations were found
in rplY or galU. One of 40 examined isolates did not express
nuoG. No mutations were found in the 16S rRNA gene in 13
examined isolates.
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